Patent and Utility Model License Agreements in Turkey: Types, Duty to Disclose, Invalidity Risk and the Use Requirement
KEY TAKEAWAY: If a licensed patent is later invalidated, the licensee does not automatically recover all royalties paid. Under Art. 139/2-b of Code 6769, the retroactive effect of invalidity does not affect contracts concluded and performed before the invalidity decision; a refund of amounts paid may only be claimed on equitable grounds (Art. 139/3). In a case where the licensee had manufactured products under the patent and the agreement had actually been performed, the Court of Cassation held that no equitable reduction of the agreed total license fee was required, even though the patents had been invalidated and the agreement had ended long before its intended term (Court of Cassation, 11th Civil Chamber, 25.09.2023, File No. 2022/476, Decision No. 2023/5316). Patent license agreements should therefore expressly regulate what happens to payment obligations in the event of invalidity, narrowing of claims or refusal of the application.
The commercial value of an invention often emerges less from the patent owner's own production than from allowing others to use it. Technology transfer from universities and R&D centres to industry, market entry by foreign patent owners through local manufacturers in Turkey, and manufacturing collaborations in sectors such as pharmaceuticals, chemicals and machinery largely derive their legal basis from patent license agreements.
This article examines the types of patent and utility model licenses under Turkish law, formal requirements and recordal, the licensor's duty to disclose and its liability, the effect of invalidity on royalties, the use requirement and compulsory license risk, and the competition law dimension, in light of recent decisions of the Turkish Court of Cassation.

Legal Framework
Patent licensing is governed by Art. 125 of the Industrial Property Code No. 6769 ("Code 6769"). The licensor's duty to disclose is set out in Art. 126, its liability in Art. 127, license offers in Art. 128 and the use requirement in Art. 130. The rules on written form and recordal applicable to all industrial property rights are in Art. 148, and the licensee's right to sue is in Art. 158. Under Art. 145, these provisions also apply to utility models unless contrary to their nature. The documents required for recordal are listed in Art. 116 of the Regulation on the Implementation of the Industrial Property Code ("Regulation"). The Turkish Patent and Trademark Office ("TPTO") keeps the register in which licenses are recorded.
A license agreement is not a contract type regulated in the Turkish Code of Obligations. The Court of Cassation treats license agreements as atypical contracts and applies, as far as possible, the rules of the contract type they most closely resemble. Most of the parties' rights and obligations should therefore be expressly regulated in the agreement.
Subject Matter: Licensing at the Application Stage
Under Art. 125/1 of Code 6769, not only a granted patent but also a patent application may be licensed. A license at the application stage gives the licensee early market access; however, the licensee is paying for a right that may or may not be granted, and whose claims are not yet settled.
If the application is withdrawn or refused, Art. 139 applies unless the parties have provided for broader liability (Art. 127/2). Application-stage licenses should therefore expressly regulate whether a lower royalty applies until grant, how the royalty will be adjusted if the claims are narrowed during examination, and what happens to the agreement if the application is refused.
Types of License
Under Art. 125/2 of Code 6769, a license may be exclusive or non-exclusive, and unless otherwise agreed, it is non-exclusive. Under a non-exclusive license, the licensor may use the invention itself and grant further licenses to third parties. Under an exclusive license, the licensor may not grant licenses to others and, unless it has expressly reserved the right, may not use the invention itself.
The structure commonly used in practice, in which the licensor reserves its own right to use (a sole license), is only effective if expressly provided for in the agreement. The type of license should therefore be defined not by a single label but by regulating together the licensor's own right to use, the prohibition on licensing third parties, the territory, the field of use and the term.
Where exclusivity is divided into periods, documenting those periods is particularly important. In a decision upheld by the Court of Cassation, an exclusive license had been granted and recorded for a patent that entered Turkey via the PCT route; the agreement provided that exclusivity periods would end on certain dates and that their continuation would be negotiated. In the infringement action, the defendant argued that the license entry had lapsed and that it was unclear whether the claimant was still a licensee. Taking into account the patent owner's letter confirming the extension of the exclusive rights, the court accepted the exclusive licensee's standing and ordered the infringement to cease (Court of Cassation, 11th Civil Chamber, 04.04.2024, File No. 2022/6329, Decision No. 2024/2766). Extensions of exclusivity amount to amendments of the agreement and should be made in writing and, where necessary, reflected in the register.
Sublicensing, Transfer and Exceeding the Scope of the License
Unless otherwise agreed, licensees may not transfer their rights under the license to third parties or grant sublicenses (Art. 125/3). In sectors where production is shared within corporate groups or contract manufacturing is common, permission to sublicense and to use contract manufacturers should be addressed specifically.
Under Art. 125/4, unless otherwise agreed, the licensee may carry out all acts relating to the use of the invention during the term of the patent; however, it must comply with the terms of the agreement, failing which the patent owner may assert its patent rights against the licensee. Art. 141/1-d expressly lists the unauthorised extension of rights granted by license, or the transfer of those rights to third parties, as patent infringement. The products, claims, fields of use and territories covered by the license should therefore be defined narrowly and clearly. A vaguely defined scope also weakens the licensor's infringement claim.
Duty to Disclose and Know-How
Under Art. 126/1 of Code 6769, unless otherwise agreed, the licensor must provide the licensee with the technical information necessary for the normal use of the invention. The licensee, in turn, must take the measures necessary to prevent the disclosure of confidential information provided to it (Art. 126/2).
In practice, patent licenses are often combined with a know-how license. Manufacturing parameters, formulation details and quality control methods not disclosed in the specification are not protected by the patent; their protection rests entirely on the contract and trade secret law. The agreement should therefore expressly regulate:
The scope, form and timetable of the technical information to be delivered,
The duration and cost of technical support, training and secondment of personnel,
The scope of confidentiality obligations and how long they survive termination,
Whether know-how fees remain payable if the patent expires or is invalidated.
Where patent and know-how fees are combined into a single royalty, separating from the outset the portion that will remain payable if the patent falls away is the most effective way of preventing future disputes.
Licensor's Liability and Invalidity of the Patent
Lack of Authority and Bad Faith
If it subsequently emerges that the licensor was not entitled to grant the license, the licensor is liable to the persons concerned (Art. 127/1). If the licensor has not informed the licensee of Turkish or foreign reports and decisions on patentability, or of what it knows in this respect, and has not included statements regarding them in the agreement, it is presumed to have acted in bad faith; a licensor acting in bad faith is always liable for its acts (Art. 127/3).
This presumption carries a clear warning for licensors: in addition to Turkish search and examination reports, adverse reports, opposition and invalidity decisions issued for foreign family patents (patent applications filed abroad for the same invention) should be listed as annexes to the agreement. For licensees, reviewing these documents is a fundamental step before the royalty rate is set.
Effect of Invalidity on Royalties
If a patent is invalidated, the decision has retroactive effect and the protection is deemed never to have arisen (Art. 139/1). However, the retroactive effect does not affect contracts concluded and performed before the invalidity decision (Art. 139/2-b). A full or partial refund of amounts paid under such contracts may be claimed on equitable grounds (Art. 139/3).
How this provision is applied in practice is clearly illustrated by a case before the Court of Cassation. An exclusive patent license had been granted for two inventions relating to the manufacture of sandwich blocks. The total license fee of TRY 100,000 was to be paid not in cash but through a 10% share in a company to be established by the licensee, TRY 1 for each square metre of product manufactured, and a consultancy fee. The patents were subsequently invalidated by a final judgment, and the agreement, intended to run for roughly seventeen years, ended after one year and seven months. The licensor sued for the unpaid amounts.
The first instance court upheld the claim, reasoning that invalidity does not affect contracts concluded and performed before the invalidity decision and that the licensee, as a prudent merchant, should have regulated in the agreement the consequences of the patent being invalidated. The regional court of appeal, noting that the agreement had ended long before its intended term, applied a 50% equitable reduction to the production-based fee. The Court of Cassation reversed, emphasising that the agreement had been performed between the parties and that the licensee had manufactured products based on the patent; the early termination of the agreement did not require an equitable reduction of the agreed total fee, and the claim had to be determined by deducting payments made, up to the total of TRY 100,000 (Court of Cassation, 11th Civil Chamber, 25.09.2023, File No. 2022/476, Decision No. 2023/5316). Although the decision was based on Art. 131 of the former Decree-Law No. 551, the same rule is now found in Art. 139 of Code 6769.
This decision has two important consequences for licensees. First, an invalidity decision does not, on its own, extinguish the payment obligation. Second, although an equitable reduction may be claimed, courts may interpret it narrowly where the licensee has actually benefited from the patent. The agreement should therefore expressly regulate:
What happens to royalty obligations if the patent is wholly or partly invalidated, the claims are narrowed, or the patent lapses for non-payment of annual fees,
Whether royalties will be suspended or paid into escrow while an invalidity action is pending,
Whether an upfront fee will be partly refunded in the event of invalidity,
The licensor's right to terminate if the licensee challenges the validity of the patent.
As to the last point, it should be borne in mind that clauses directly prohibiting the licensee from challenging the validity of the patent must be assessed separately from a competition law perspective.
The Use Requirement and Compulsory License Risk
Under Art. 130/1 of Code 6769, the patent owner or a person authorised by it must use the patented invention. After the later of three years from publication of the grant in the Bulletin or four years from the filing date, any interested person may request a compulsory license if the invention is not being used, if no serious and genuine preparations for use have been made, or if use does not meet the needs of the national market. The same applies where use has been interrupted for more than three consecutive years without justification (Art. 130/2).
By referring to "a person authorised by it", the Code treats use by a licensee as use by the patent owner. This means that, particularly for foreign patent owners with no production of their own in Turkey, a license can serve as protection against compulsory license risk. For that, however, the licensee must actually use the invention to a sufficient extent. The agreement should therefore regulate:
Minimum production or sales targets and the consequences of failing to meet them,
Regular reporting of use and delivery of evidence of use to the licensor,
Cooperation between the parties on notifying use to the TPTO (declaration of use).
Under Art. 117/8 of the Regulation, a declaration that the patent is being used, or cannot be used, is filed with the TPTO within the above period, recorded in the register and published in the Bulletin; patents for which no declaration of use is filed within that period are also published in the Bulletin. Objective technical, economic or legal reasons such as regulatory approval and compliance with standards are accepted as justified reasons for non-use (Regulation, Art. 117/7). In sectors with lengthy approval procedures, such as pharmaceuticals and medical devices, documenting these reasons is particularly important. Where a compulsory license is granted, the provisions on contractual licenses apply unless the provisions on compulsory licenses provide otherwise (Art. 137); a compulsory licensee may not grant sublicenses (Art. 133/2), and a compulsory license may only be transferred together with the business or the relevant part of it (Art. 135).
License Offers and Exclusive Licenses
The patent owner may, by written request to the TPTO, declare that it will grant a license to anyone wishing to use the invention; the offer is published in the Bulletin and may be withdrawn at any time (Arts. 128/1 and 128/3). A license offer is incompatible with an exclusive license. No license offer may be made while an exclusive license is recorded (Art. 128/2), and an exclusive license cannot be recorded unless a pending license offer is withdrawn (Regulation, Art. 117/5-6). Where an exclusive license is being negotiated, it should therefore be checked in advance whether a license offer has been published in the register and, if necessary, withdrawal of the offer should be made a condition precedent to the agreement.
Co-Ownership and Surrender
Where a patent is co-owned, licensing to third parties requires the unanimous consent of the co-owners; if unanimity cannot be reached, the court may, on equitable grounds, confer the power to license on one or more of them (Art. 112/2). For patents resulting from joint R&D projects, regulating the power to license from the outset in a co-ownership agreement is therefore a commercial necessity.
An important rule protecting licensees concerns surrender. The patent owner cannot surrender the patent without the consent of recorded licensees (Art. 140/5). This protection applies only to recorded licenses. Since the licensor may also surrender one or more claims (Art. 140/3), it is recommended that the agreement also require the licensee's consent for acts that would narrow the scope of the claims.
Recordal and the Right to Sue
A license agreement must be in writing (Art. 148/4). Unlike assignments, notarization is not required for licenses. However, rights arising from unrecorded licenses cannot be asserted against third parties acting in good faith (Art. 148/5). Under Art. 116 of the Regulation, the license agreement submitted for recordal must contain the signatures and declarations of the parties, the number of the patent application or patent, the term of the license, the fee if any, and the type of license. Where the commercial terms are to remain confidential, a short license summary containing only these minimum elements may be prepared and used for recordal.
The licensee's right to sue for infringement is governed by Art. 158. Unless otherwise agreed, an exclusive licensee may bring in its own name the actions available to the patent owner. A non-exclusive licensee, unless its right to sue is expressly restricted in the agreement, must first request by notice that the patent owner bring the action; if the owner refuses or does not bring the action within three months of the notice, the licensee may sue in its own name, to the extent of its own interest, attaching the notice. Where there is a risk of serious harm, the licensee may request a preliminary injunction before the three-month period expires (Art. 158/3). In practice, it is recommended that these powers be expressly regulated so that the licensee can act quickly in infringement actions, preliminary injunctions and customs measures.
Competition Law Dimension
Patent license agreements should be assessed under Art. 4 of the Law on the Protection of Competition No. 4054 where they contain, in particular, exclusivity, territorial and customer restrictions, price or quantity limitations, obligations to license back improvements to the licensor (grant-back) or clauses prohibiting challenges to the patent's validity (no-challenge). For technology transfer agreements, the Competition Board's Block Exemption Communiqué on Technology Transfer Agreements (Communiqué No. 2008/2) grants a block exemption to agreements below certain market share thresholds. However, the communiqué also lists hardcore restrictions that prevent the exemption from applying and obligations that fall outside its scope. Particularly where market shares are high or the license is concluded between competitors, the provisions of the agreement should be examined separately under this communiqué.
Conclusion
Although a patent license agreement can be concluded in writing without notarization, the most serious consequences for the parties often arise from matters on which the agreement is silent. A license that does not regulate what happens to payments upon invalidity may leave the licensee paying for an invalid patent. A license that does not address the use requirement may expose the licensor to compulsory license requests. An unrecorded license may render ineffective one of the licensee's strongest protections, namely that the licensor cannot unilaterally surrender the patent. Patent licenses should therefore be prepared with an approach that takes into account both the specific rules of patent law and competition law.
Legislation and Case Law Referred To
Industrial Property Code No. 6769, Arts. 112, 125, 126, 127, 128, 130, 133, 135, 137, 139, 140, 141, 145, 148, 158 · Regulation on the Implementation of the Industrial Property Code, Arts. 116, 117 · Law on the Protection of Competition No. 4054, Art. 4 · Block Exemption Communiqué on Technology Transfer Agreements (No. 2008/2)
Court of Cassation, 11th Civil Chamber: 25.09.2023, 2022/476 – 2023/5316 · 04.04.2024, 2022/6329 – 2024/2766 · 22.06.2021, 2020/6694 – 2021/5284
This article is intended for general information purposes only and does not constitute legal advice.
To prepare and negotiate patent, utility model and know-how license agreements in Turkey, structure technology transfer arrangements, and record licenses with the TPTO, please contact us at info@goklulaw.com.
Key Contact:
Evren Fırat Göklü
Founding Partner | Attorney at Law | Trademark & Patent Attorney



